论文部分内容阅读
罗格列酮是新一代噻唑烷二酮类药物,最先由葛兰素史克公司研制,1999年美国FDA审核批准上市,为胰岛素增敏剂,是2型糖尿病口服药物治疗领域的重大突破,现广泛应用于2型糖尿病的治疗。这类药物直接从减轻胰岛素抵抗方面来干预糖尿病的病程,达到降糖与改善糖尿病血管并发症危险因素的治疗目的。林华等[1]在比较4种口服降糖药治疗2型糖尿病,结果得出罗格列酮最优。现将近年来临床应用情况介绍如下。
Rosiglitazone is a new generation of thiazolidinedione drugs, first developed by GlaxoSmithKline, FDA approved the listing in 1999 for the insulin sensitizer, is a major breakthrough in the field of oral drug treatment of type 2 diabetes, Is now widely used in the treatment of type 2 diabetes. These drugs directly interfere with the course of diabetes in terms of reducing insulin resistance and achieve the purpose of reducing blood sugar and improving the risk factors of diabetic vascular complications. Lin Hua et al [1] in the comparison of four kinds of oral hypoglycemic agents in the treatment of type 2 diabetes, the results obtained rosiglitazone optimal. Now clinical application in recent years are described below.